Ignite Creation Date:
2025-12-24 @ 1:41 PM
Ignite Modification Date:
2025-12-29 @ 5:15 PM
Study NCT ID:
NCT05909995
Status:
TERMINATED
Last Update Posted:
2025-02-18
First Post:
2023-06-09
Is Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
Interventional Study of INCB 99280 With Ipilimumab in Participants With Select Solid Tumors
Sponsor:
Incyte Corporation
Organization:
Study Overview
Official Title:
A Phase 1 Study of INCB099280 in Combination With Ipilimumab in Participants With Select Solid Tumors
Status:
TERMINATED
Status Verified Date:
2025-02
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
This was a strategic business decision. There were no safety concerns contributing to this decision.
Has Expanded Access:
False
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
The purpose of this study is to characterize the safety, tolerability, PK, and efficacy of INCB 99280 in combination with ipilimumab in participants with select solid tumors.
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
True
Is a FDA Regulated Device?:
False
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
Secondary ID Infos
| Secondary ID | Type | Domain | Link | View |
|---|---|---|---|---|
| 2023-503243-34-00 | REGISTRY | EU CT Number | View |